In this proof-of-concept study, we employed an invasive, orthotopic GBM model to study the in vivo effect of the commercially available InVivoPlex targeted RGD-NP loaded with βPix/COOL-1 siRNA when delivered in combination with Bev. Here, ARHGEF7 is linked to glioblastoma.